OTCMKTS:MATN - Mateon Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2083 0.00 (-2.21 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$0.2130
Today's Range$0.19 - $0.2140
52-Week Range$0.0901 - $0.55
Volume8,600 shs
Average Volume43,994 shs
Market Capitalization$8.09 million
P/E Ratio-0.40
Dividend YieldN/A
Beta2.16
Mateon Therapeutics logoMateon Therapeutics, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating neuroendocrine tumors. The company also develops OXi4503 that is in Phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

Receive MATN News and Ratings via Email

Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MATN
CUSIPN/A
Phone650-635-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio0.26
Quick Ratio0.26

Price-To-Earnings

Trailing P/E Ratio-0.40
Forward P/E Ratio-1.16
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-10.42

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-13,810,000.00
Net MarginsN/A
Return on Equity-802.11%
Return on Assets-384.06%

Miscellaneous

Employees5
Outstanding Shares41,420,000
Market Cap$8.09

Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics Inc (OTCMKTS:MATN) posted its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.01. View Mateon Therapeutics' Earnings History.

What price target have analysts set for MATN?

2 brokerages have issued 1 year price targets for Mateon Therapeutics' shares. Their forecasts range from $1.00 to $1.00. On average, they expect Mateon Therapeutics' stock price to reach $1.00 in the next twelve months. This suggests a possible upside of 380.1% from the stock's current price. View Analyst Ratings for Mateon Therapeutics.

What is the consensus analysts' recommendation for Mateon Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mateon Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Mateon Therapeutics' key competitors?

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the folowing people:
  • Dr. William D. Schwieterman, Chairman, CEO & Pres (Age 60)
  • Mr. Matthew M. Loar, Chief Financial Officer (Age 55)
  • Ms. Shari Annes, Exec. Officer of Investor Relations
  • Dr. Yuval Binur Ph.D., Exec. VP of Financial
  • Ms. Pamela Ha, Controller

Has Mateon Therapeutics been receiving favorable news coverage?

Media headlines about MATN stock have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mateon Therapeutics earned a media sentiment score of 0.02 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 45.38 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Mateon Therapeutics?

Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of MATN stock can currently be purchased for approximately $0.2083.

How big of a company is Mateon Therapeutics?

Mateon Therapeutics has a market capitalization of $8.09 million. The biopharmaceutical company earns $-13,810,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Mateon Therapeutics employs 5 workers across the globe.

How can I contact Mateon Therapeutics?

Mateon Therapeutics' mailing address is 701 GATEWAY BLVD SUITE 210, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]


MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.